Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

109.85 +2.46 (+2.29%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

These stocks that are showing activity before the opening bell on Monday. ↗

June 02, 2025

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 02, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 30, 2025

Via Benzinga

Friday's after hours session: top gainers and losers ↗

May 30, 2025

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

What's Next: Kymera Therapeutics's Earnings Preview ↗

May 08, 2025

Via Benzinga

Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviews ↗

February 28, 2025

Via Benzinga

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts ↗

May 12, 2025

Via Benzinga

Earnings Scheduled For May 9, 2025 ↗

May 09, 2025

Via Benzinga

Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio? ↗

April 27, 2025

Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics.

Via Benzinga

Topics Artificial Intelligence

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

The Latest Analyst Ratings For Kymera Therapeutics ↗

November 01, 2024

Via Benzinga

Preview: Kymera Therapeutics's Earnings ↗

October 30, 2024

Via Benzinga

Why Kymera Therapeutics Stock Crushed it This Week ↗

April 25, 2025

Via The Motley Fool

Insights Ahead: Kymera Therapeutics's Quarterly Earnings ↗

October 30, 2024

Via Benzinga

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

The Analyst Landscape: 7 Takes On Kymera Therapeutics ↗

September 27, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics ↗

September 09, 2024

Via Benzinga

This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday ↗

August 26, 2024

Via Benzinga

Unveiling 6 Analyst Insights On Kymera Therapeutics ↗

August 12, 2024

Via Benzinga

Why Kymera Therapeutics Stock Is Soaring Today ↗

July 09, 2024

Kymera's lead pipeline candidate received some good news.

Via The Motley Fool

Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics ↗

June 17, 2024

Via Benzinga

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

August 07, 2024

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

July 31, 2024

From Kymera Therapeutics, Inc.

Via GlobeNewswire

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details ↗

July 14, 2024

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Via Benzinga

Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 09, 2024

Via Benzinga

Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday ↗

July 09, 2024

Via Benzinga

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

July 09, 2024

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

July 08, 2024

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

June 20, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END

Via FinancialNewsMedia

Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

June 20, 2024

From FN Media Group LLC

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.